#1 Clinical Trials Search in Europe

Nelarabine

Nelarabine, also known as Arranon or compound 506U78, is an investigational drug being studied in clinical trials for various T-cell malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). This article explores the ongoing research into nelarabine’s safety, efficacy, and potential applications in treating these challenging blood cancers.

Table of Contents

What is Nelarabine?

Nelarabine is a chemotherapy drug used to treat certain types of blood cancers. It’s also known by several other names, including:

  • 506U78
  • Arranon
  • Atriance
  • Compound 506U78
  • GW506U78
These different names all refer to the same medication[2][3][4].

Nelarabine is what’s called a prodrug. This means it’s converted into its active form, called ara-G, inside the body. Ara-G is similar to a natural substance in our DNA called deoxyguanosine[5].

What Conditions Does Nelarabine Treat?

Nelarabine is primarily used to treat:

  • T-cell acute lymphoblastic leukemia (T-ALL): This is a type of blood cancer that affects a specific kind of white blood cell called T-lymphocytes.
  • T-cell lymphoblastic lymphoma (T-LBL): This is a similar cancer that affects the lymph nodes and other lymphoid tissues.
It’s typically used when these cancers have not responded to at least two other chemotherapy treatments, or have come back after previous treatment (known as relapsed or refractory disease)[1][3].

In some clinical trials, Nelarabine has also been studied for use in other types of lymphomas, including:

  • Cutaneous T-cell lymphoma (CTCL)
  • Peripheral T-cell lymphoma (PTCL)
  • Various types of non-Hodgkin’s lymphoma
However, its use in these conditions is still considered investigational[2][4].

How Does Nelarabine Work?

Nelarabine belongs to a class of drugs called antimetabolites. It works by interfering with the DNA of cancer cells. Specifically:

  • It gets converted into ara-G in the body
  • Ara-G is similar to a building block of DNA called deoxyguanosine
  • Cancer cells mistake ara-G for deoxyguanosine and incorporate it into their DNA
  • This disrupts the cancer cell’s ability to make new DNA, which it needs to divide and grow
  • As a result, the cancer cells stop dividing and eventually die
This mechanism allows Nelarabine to target rapidly dividing cells, such as cancer cells[6].

How is Nelarabine Administered?

Nelarabine is typically given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The usual schedule is:

  • Given over 2 hours
  • On days 1, 3, and 5 of a treatment cycle
  • Cycles are usually repeated every 21 to 28 days
The exact dose and schedule can vary depending on your specific condition, overall health, and how well you tolerate the treatment[2][3].

In some clinical trials, researchers have also studied giving Nelarabine as a continuous infusion over 5 days, but this is not the standard method of administration[6].

Clinical Trials and Research

Nelarabine has been the subject of numerous clinical trials to evaluate its effectiveness and safety. Some key findings include:

  • It has shown effectiveness in both children and adults with relapsed or refractory T-ALL or T-LBL
  • Response rates (meaning the percentage of patients whose cancer shrinks or disappears) have varied across studies, but have been promising for patients who have few other treatment options
  • Researchers have studied its use alone and in combination with other chemotherapy drugs
  • Some studies have looked at using Nelarabine earlier in treatment, such as during the initial treatment (called induction) or as part of the treatment to prevent relapse (called consolidation)
These trials help doctors understand how to best use Nelarabine and who is most likely to benefit from it[5][7].

Potential Side Effects

Like all chemotherapy drugs, Nelarabine can cause side effects. Some of the most important ones to be aware of include:

  • Neurological effects: This can include numbness or tingling in hands and feet, balance problems, or confusion. These are considered some of the most significant side effects to watch for.
  • Blood-related effects: Nelarabine can lower your blood cell counts, which can increase your risk of infection, bleeding, or anemia.
  • Nausea and vomiting
  • Fatigue
  • Headache
Your healthcare team will monitor you closely for these and other side effects. They may give you medications to help prevent or manage side effects, such as anti-nausea drugs[1][5][6].

Special Considerations

There are a few special situations where Nelarabine might be used differently:

  • Kidney or liver problems: If you have impaired kidney or liver function, your doctor might adjust your dose of Nelarabine.
  • Young adults: Some studies have specifically looked at using Nelarabine in young adults (up to age 21 or sometimes up to age 59) with T-ALL or T-LBL.
  • Before stem cell transplant: In some cases, Nelarabine might be used to help achieve remission before a stem cell transplant.
Your doctor will consider these and other factors when deciding if Nelarabine is right for you and how to use it in your specific situation[8][5][7].

Aspect Details
Drug Name Nelarabine (also known as Arranon, 506U78)
Primary Indications T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoblastic lymphoma (T-LBL)
Administration Intravenous infusion, typically over 2 hours on days 1, 3, and 5 of a 21-28 day cycle
Key Outcomes Measured Safety, efficacy, remission rates, survival rates, pharmacokinetics, pharmacodynamics
Patient Population Primarily relapsed or refractory T-ALL/T-LBL patients, including children and adults
Notable Side Effects Neurological adverse events, blood disorders, nausea
Current Status In various phases of clinical trials, including post-marketing observational studies

FAQ

  • What is nelarabine and how does it work? Nelarabine is a chemotherapy drug that interferes with DNA in cancer cells to stop them from growing and dividing. It is a prodrug that gets converted in the body to a compound that specifically targets T-cells.
  • What types of cancer is nelarabine being studied for? Nelarabine is primarily being investigated for T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Some trials are also studying it for other T-cell lymphomas.
  • How is nelarabine administered in clinical trials? In most trials, nelarabine is given as an intravenous (IV) infusion over 2 hours on days 1, 3, and 5 of a treatment cycle. Cycles are typically repeated every 21-28 days.
  • What are some potential side effects of nelarabine? Common side effects being monitored include neurological effects, low blood cell counts, and nausea. Researchers are particularly focused on tracking any neurological adverse events.
  • Who is eligible to participate in nelarabine clinical trials? Eligibility varies by trial, but most focus on patients with relapsed or refractory T-ALL or T-LBL who have not responded to or have relapsed following at least two prior chemotherapy regimens.

Ongoing Clinical Trials on Nelarabine

  • Study on Changes in [18F]F-AraG Uptake After Radiotherapy in Patients with Non-Small Cell Lung Cancer, Melanoma, Breast Cancer, and Esophageal Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Testing F-18-AraG imaging scan reliability in patients with lung cancer using repeat scans

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on PET Tracers [18F]F-AraG and [89Zr]Zr-Df-Crefmirlimab for Evaluating T Cell Activation in Non-Small Cell Lung Cancer Patients

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • T-cell acute lymphoblastic leukemia (T-ALL): A type of blood cancer that affects T-lymphocytes, a kind of white blood cell. It progresses quickly and requires immediate treatment.
  • T-cell lymphoblastic lymphoma (T-LBL): A type of non-Hodgkin lymphoma that affects T-lymphocytes. It is similar to T-ALL but primarily involves lymph nodes rather than bone marrow.
  • Relapsed: When cancer returns after a period of improvement or remission following treatment.
  • Refractory: When cancer does not respond to treatment or stops responding after initial improvement.
  • Prodrug: An inactive substance that is converted into an active drug within the body after administration.
  • Intravenous (IV): Administration of a substance directly into a vein.
  • Remission: A decrease in or disappearance of signs and symptoms of cancer. In partial remission, some signs of cancer remain; in complete remission, all signs of cancer have disappeared.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body and the mechanisms of drug action.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.

References

  1. https://clinicaltrials.gov/study/NCT01376115
  2. https://clinicaltrials.gov/study/NCT00005080
  3. https://clinicaltrials.gov/study/NCT00684619
  4. https://clinicaltrials.gov/study/NCT00005950
  5. https://clinicaltrials.gov/study/NCT00866671
  6. https://clinicaltrials.gov/study/NCT01094860
  7. https://clinicaltrials.gov/study/NCT02619630
  8. https://clinicaltrials.gov/study/NCT00004239